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Sensitivity to rewarding and reinforcing drug effects has a critical role in initial use, but
the role of initial aversive drug effects has received less attention. Methamphetamine
effects on dopamine re-uptake and efflux are associated with its addiction potential.
However, methamphetamine also serves as a substrate for the trace amine-associated
receptor 1 (TAAR1). Growing evidence in animal models indicates that increasing
TAAR1 function reduces drug self-administration and intake. We previously determined
that a non-synonymous single nucleotide polymorphism (SNP) in Taar1 predicts a
conformational change in the receptor that has functional consequences. A Taar1m1J
mutant allele existing in DBA/2J mice expresses a non-functional receptor. In comparison
to mice that possess one or more copies of the reference Taar1 allele (Taar1+/+ or
Taar1+/m1J ), mice with the Taar1m1J/m1J genotype readily consume methamphetamine,
express low sensitivity to aversive effects of methamphetamine, and lack sensitivity to
acute methamphetamine-induced hypothermia. We used three sets of knock-in and
control mice in which one Taar1 allele was exchanged with the alternative allele to
determine if other methamphetamine-related traits and an opioid trait are impacted by
the same Taar1 SNP proven to affect MA consumption and hypothermia. First, we
measured sensitivity to conditioned rewarding and aversive effects of methamphetamine
to determine if an impact of the Taar1 SNP on these traits could be proven. Next,
we used multiple genetic backgrounds to study the consistency of Taar1 allelic effects
on methamphetamine intake and hypothermia. Finally, we studied morphine-induced
hypothermia to confirm prior data suggesting that a gene in linkage disequilibrium
with Taar1, rather than Taar1, accounts for prior observed differences in sensitivity. We
found that a single SNP exchange reduced sensitivity to methamphetamine conditioned
reward and increased sensitivity to conditioned aversion. Profound differences in
methamphetamine intake and hypothermia consistently corresponded with genotype at
the SNP location, with only slight variation in magnitude across genetic backgrounds.
Morphine-induced hypothermia was not dependent on Taar1 genotype. Thus, Taar1
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genotype and TAAR1 function impact multiple methamphetamine-related effects that
likely predict the potential for methamphetamine use. These data support further
investigation of their potential roles in risk for methamphetamine addiction and
therapeutic development.
Keywords: aversion, CRISPR-Cas9, hypothermia, knock-in, morphine, pleiotropic, selective breeding, two-bottle
choice

INTRODUCTION

Taar1m1J allele consume more MA on average than mice that
possess one or two copies of the reference Taar1+ allele.
In addition to identifying genetic differences related to the
bidirectional selection response, selectively bred lines provide
information about genetically correlated traits, defined as
phenotypes that are impacted by one or more of the genes that
influence the selection trait. Several MA-related traits reliably
differentiate the MA drinking (MADR) lines. These include
rewarding and aversive traits, as well as a physiological trait,
MA-induced hypothermia, proposed to be among the aversive
effects of MA that inhibit MA intake (20, 25, 26). Herein, we
report studies performed in three sets of matched KI and control
line mice in which one Taar1 allele was exchanged with the
alternative allele. First, MAHDR-Taar1+/+ KI and control mice
were studied for tastant intake and preference, and sensitivity
to two traits hypothesized to be pleiotropically influenced by
Taar1: sensitivity to MA-induced conditioned place preference
and conditioned taste aversion. Based on previous findings (16,
18, 21, 22, 27), we predicted that the KI and control mice
would not differ in saccharin or quinine intake or preference,
KI of the Taar1+ allele would decrease sensitivity to MA-induced
conditioned place preference, and KI of the Taar1+ allele would
increase sensitivity to MA-conditioned taste aversion. Next, KI
mice generated on the MADR progenitor C57BL/6J and DBA/2J
background strains were studied for MA intake and MA-induced
hypothermia to examine replication of Taar1 effects on different
genetic backgrounds. These traits have already been confirmed to
be impacted by Taar1 in the MAHDR KI and control lines (21).
Finally, previous data in MADR mice suggest that a difference
in sensitivity to morphine-induced hypothermia was not a
pleiotropic effect of Taar1, but more likely due to a linked
polymorphism (25). To confirm this, we examined this trait
in the MAHDR-Taar1+/+ KI and control mice and predicted
comparable morphine-induced hypothermia.

Considerable research has focused on drug use disorders
as motivational disorders involving inherent or drug-induced
reward pathway function. Human and animal research supports
a critical role for circuitry underlying sensitivity to rewarding
and reinforcing drug effects in risk for continued use,
neuroadaptation and relapse. Less is known about factors that
reduce risk for addiction such as, for example, the protective
role of sensitivity to aversive or adverse drug effects. Although
there is important research in this area for alcohol (1–4), it
has not been a focus of psychostimulant research or therapeutic
development for psychostimulant addiction. To address initial
sensitivity to drug aversive effects in humans requires knowledge
of initial drug effects and the inclusion of individuals in studies
who have tried a drug, but did not continue to use because they
found the effects to be unpleasant. This is not the typical research
performed in the addiction field; rather individuals suffering
from a substance use disorder, or with a significant history of
drug use, are compared to individuals with a low to modest drug
history. Concerns about potential long-term consequences on
behavior and in the brain, of even relatively low-level exposure
to drugs like methamphetamine (MA) (5–14), raise concerns
about conducting such research in drug-naïve humans. However,
the study of drug avoiders could lead to the identification of a
new class of therapeutics. Animal models of drug use have an
important role in this area of study, because drug history can be
controlled and initial responses readily measured.
Bidirectional selective breeding has the explicit goal of
creating animal lines that exhibit a low vs. high level of a
particular characteristic. We bred mice for level of voluntary MA
intake and created MA high drinking (MAHDR) and MA low
drinking (MALDR) lines of mice that consume binge-like levels
of MA or avoid consuming MA, respectively (15–18). Using this
model, we determined that a single nucleotide polymorphism
(SNP) at position 229 in the trace amine-associated receptor
1 gene (Taar1) accounts for 60% of the heritable variance in
MA intake (19–21). The non-synonymous SNP (rs33645709) is
found in DBA/2J mice sourced from The Jackson Laboratory
(JAX), but not in DBA/2 mice sourced from other suppliers
(22) or in any of the 28 other strains that have been genotyped
at this genetic location (23, 24). This coding variant changes a
proline to a threonine in the second transmembrane domain
of the receptor (24). Multiple lines of evidence, beginning with
quantitative trait locus mapping and culminating in the use of
a CRISPR-Cas9-derived knock-in (KI) model on the MAHDR
background, definitively determined that this Taar1 SNP impacts
level of MA consumption (21). Thus, mice homozygous for the
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MATERIALS AND METHODS
Subjects
Subjects were male and female MAHDR-Taar1+/+ KI, DBA/2JTaar1+/+ KI, C57BL/6J-Taar1m1J/m1J KI, and control lines
matched to each KI line (MAHDR-Taar1m1J/m1J , DBA/2JTaar1m1J/m1J , and C57BL/6J-Taar1+/+ ). The MAHDR KI mice
were created at the Oregon Health & Science University
Transgenic Mouse Models Shared Resource, utilizing CRISPRCas9 technology to replace the Taar1m1J allele with the reference
Taar1+ allele; controls were derived from those mice in which
the Taar1m1J allele was not successfully excised and replaced;
thus, they retained the Taar1m1J/m1J genotype. Details can be
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Experiment 1: Novel Tastant Intake and
Preference in MAHDR-Taar1+/+ KI and
MAHDR-Taar1m1J/m1J Control Mice

found in Stafford et al. (21). The identical process was applied at
JAX (Bar Harbor, ME, USA) to generate the same KI on a pure
DBA/2J inbred strain background, or to replace the reference
Taar1+ allele with the Taar1m1J allele on a pure C57BL/6J inbred
strain background.
Mice participating in the current studies were either born
within the VA Portland Health Care System (VAPORHCS)
Veterinary Medical Unit or within a breeding colony at JAX;
location for each study is indicated in experiment descriptions.
Breeders (pairs at VAPORHCS; harems at JAX) were maintained
in standard acrylic plastic shoebox cages on corncob bedding
(The Andersons, Maumee, Ohio; VAPORHCS) or pine shavings
(Hancock Lumber, Bethel, Maine; JAX), with wire lids and
filter tops. Breeding cages resided on Thoren racks under
a standard 12:12 light:dark cycle, and mice were weaned at
21 ± 2 days of age into same-sex groups of 2–4 per cage.
During breeding and experiments, mice were maintained in
climate-controlled rooms under a standard 12:12 light:dark
cycle with lights on at 0600 h, and free access to water (tap
water at the VAPORHCS; filtered and acidified at JAX) and
rodent block food (Purina 5001 or 5LOD PicoLab Rodent Diet;
Animal Specialties, Woodburn, Oregon at the VAPORHCS;
NIH315K52 chow Lab Diet 6%PM Nutrition, St. Louis MO,
USA at JAX); exceptions are noted in experimental methods.
All animal care and testing procedures were approved by
the VAPORHCS or JAX Institutional Animal Care and Use
Committee, and were conducted in compliance with the National
Institutes of Health Guidelines for Care and Use of Laboratory
Animals. Group sizes for each experiment are given in the
figure captions.

We characterized saccharin (SACC) and quinine (QUIN) intake
and preference to investigate whether a difference in tastant
intake or preference corresponds with the difference in MA
intake found in a previous study between the MAHDR-Taar1+/+
KI and MAHDR-Taar1m1J/m1J control mice (21). This study was
conducted at the VAPORHCS using methods consistent with our
previous studies in the MADR mice (16, 18). Male and female
mice were weighed, singly-housed, and given access to two waterfilled 25-ml graduated cylinders fitted with stoppers and sipper
tubes for 2 consecutive days to familiarize them with drinking
fluid from these tubes. Using a counterbalanced design, mice
were then offered water vs. SACC and then water vs. QUIN or the
two tastants in the alternate order. Tastants were offered 24 h/day
in two increasing concentrations for 4 days each and mice were
weighed every 4 days; therefore, the two-bottle choice tastant
phase included days 3–18. The positions of the water and tastant
tubes were alternated every 2 days, the SACC concentrations
were 1.6 and 3.2 mM, and the QUIN concentrations were 0.015
and 0.03 mM, consistent with our previous studies (16, 18).
Consumption was measured each day in ml. Mice were tested at
an average age of 81 ± 1 days, with a range of 77–87 days.

Experiment 2: MA-Induced Conditioned
Place Preference Testing in
MAHDR-Taar1+/+ KI and
MAHDR-Taar1m1J/m1J Control Mice
Group housed (2–4 per cage) male and female MAHDRTaar1+/+ KI and MAHDR-Taar1m1J/m1J control mice were
tested for sensitivity to conditioned place preference induced by
0.5 mg/kg MA, a dose that has produced consistent preference in
MAHDR and no preference in MALDR mice (16, 18). This study
was conducted at the VAPORHCS using our established unbiased
place conditioning procedure. Custom-built conditioning boxes
(30 cm × 15 cm × 15 cm; San Diego Instruments, San Diego,
CA USA) were housed in sound attenuating, illuminated and
ventilated chambers. Each conditioning box had a removable
central black wall used to sequester the animal to the left or
right half of the chamber during conditioning trials; the wall
was removed during preference tests. Removable floor panels
with unique textures served as conditioning cues. One floor was
composed of 2.3 mm stainless steel rods mounted 6.4 mm apart
(the “grid” floor); the other was a stainless steel sheet with 6.4 mm
round holes on 9.5 mm staggered centers (the “hole” floor).
Animal location was detected by photocell beam interruptions
and automatically converted to time spent on a particular floor
type; photocell beam interruptions were also recorded as a
measure of locomotor activity.
The study began on a Monday and excluded weekends, and
mice were returned to group housing (2–4 per cage) each day
after testing. Mice were moved to the procedure room each
day 1 h before conditioning or testing. Initial preference for the
cues was determined in a 30-min test; mice were injected with
saline immediately prior to placement in the box. Beginning

Genotyping
All KI and control offspring used in these studies
were genotyped for Taar1 using an rtPCR method
developed in our laboratory for the relevant Taar1
SNP, based on a standard Taqman (ThermoFisher
Scientific) assay in which fluorescent probes were used for
differentiation (22).

Drugs
(+)Methamphetamine hydrochloride was purchased from
Sigma-Aldrich (St. Louis, MO, USA) or obtained from the
National Institutes of Health, National Institute on Drug Abuse
drug supply program (Rockville, MD, USA) and dissolved in tap
water for drinking or in sterile 0.9% saline (Baxter Healthcare
Corp., Deerfield, IL, USA) for injection. Sodium chloride for
conditioned taste aversion studies, and saccharin and quinine
for novel tastant intake studies, were purchased from SigmaAldrich and dissolved in tap water. Morphine was obtained
from the NIDA Drug Supply program (Rockville, MD, USA)
and dissolved in sterile saline. Saline vehicle served as a 0 dose
control treatment for MA and morphine injection studies. All
injections were delivered intraperitoneally (IP) in a volume of
10 ml/kg.
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24 h later, there were 12 alternating conditioning trials (one
daily), six immediately after saline, and six immediately after 0.5
mg/kg MA treatment that were 15 min in duration. Half of the
mice had MA paired with the grid floor and half with the hole
floor, with left/right placement of floor types counterbalanced.
A 30-min “drug-free” preference test was performed the day
after the last conditioning trial; mice were treated with saline
immediately prior to placement in the box. Finally, a 30-min
“drug-present” preference test was performed 2 days after the
drug-free preference test (after a weekend break); mice were
treated with MA immediately prior to placement in the box. Mice
were tested at an average age of 91 ± 1 days, with a range of
73–107 days; mice were tested between 1000 and 1400 h.

stoppers (Fisher Scientific, Pittsburgh, PA, USA) and single ballbearing stainless steel sipper tubes (Sta Pure Systems, Carnegie,
PA, USA) to provide experience with consuming fluid from
these tubes. On test days 2–5, mice were offered one water tube
and a tube containing a 10 mg/L solution of MA in water.
On days 6–17, the tubes contained water vs. 20 mg/L, then
40 mg/L, and then 80 mg/L MA, with each MA concentration
offered for 4 consecutive days. During the MA phase, mice had
access to MA 24 h/day and tubes were weighed prior to cage
placement and again every 48 h. Changes in MA concentration
were accompanied by fresh tubes and switching of the position
of the water vs. MA tube to account for potential side bias in
fluid intake. Mice were weighed on days 1 and 17 of the study,
and weights on those days were averaged to approximate mg/kg
MA consumed. Two separate studies were conducted. The first
included DBA/2J-Taar1+/+ KI and DBA/2J-Taar1m1J/m1J control
mice, tested at an average age of 72 ± 2 days, with a range of
56–88 days. The other included C57BL/6J-Taar1m1J/m1J KI and
C57BL/6J-Taar1+/+ control mice, tested at an average age of 75
± 1 days, with a range of 55–88 days.

Experiment 3: MA-Induced Conditioned
Taste Aversion Testing in MAHDR-Taar1+/+
KI and MAHDR-Taar1m1J/m1J Control Mice
Male and female MAHDR-Taar1+/+ KI and MAHDRTaar1m1J/m1J control mice were tested for sensitivity to
conditioned taste aversion induced by 2 mg/kg MA, a dose that
has produced consistent differences in mice with different Taar1
genotypes (22, 27). This study was conducted at the VAPORHCS
using our established procedures. A novel 0.2 M NaCl solution
was offered as the conditioned cue just prior to MA treatment to
create an association with the interoceptive effects of MA. Briefly,
mice were weighed, singly-housed, and familiarized to drinking
water from a 10-ml graduated cylinder fitted with a sipper tube
(study days −1 and 0). Water access was then limited to 2 h
per day for a 4-day acclimation period to induce motivation
to drink the novel NaCl solution at a particular time of each
day (study days 1–4). Beginning on day 5, the NaCl solution
was offered for 1 h every other day for 6 presentations (days
5, 7, 9, 11, 13, and 15). No treatment was given after the first
presentation, which was a trial intended to reduce neophobia.
On the remaining NaCl access days, with the exception of the
last, saline or MA was injected immediately after the drinking
period. NaCl consumption was measured in ml. To ensure
proper hydration, 3 h post-injection, mice were given access to
water for 30 min, and they had 2 h water access on days between
trials. Mice were tested at an average age of 93 ± 1 days, with a
range of 82–112 days; NaCl access occurred at 0900–1000 h.

Experiments 6 and 7: MA-Induced Body
Temperature Changes in DBA/2J-Taar1+/+
and DBA/2J-Taar1m1J/m1J Control, and in
C57BL/6J-Taar1m1J/m1J KI and
C57BL/6J-Taar1+/+ Control Mice
Male and female mice were tested for the effect of 2 mg/kg
MA on core body temperature using our established procedures.
This MA dose consistently produces hypothermia in MALDR
mice and other mice that possess Taar1+ , a response that is
absent in MAHDR mice and other mice that lack TAAR1
function (20, 22). This study was conducted at the VAPORHCS
using our established procedures. Mice were moved to the
procedure room at 0800–0830 h, weighed, isolated in acrylic
plastic cubicles to prevent huddling-associated body temperature
changes, and left undisturbed for 1 h to acclimate to the
testing environment, maintained at a temperature of 21 ±
1◦ C. A baseline temperature was then obtained at 0900–0930 h,
designated as time 0 (T0), using a 5 mm glycerin-coated rectal
probe attached to a Thermalert TH-8 digital thermometer
(Sensortek, Clifton, New Jersey). Mice were then immediately
treated with saline or 2 mg/kg MA and returned to their holding
cubicles. Temperatures were subsequently obtained at T30, T60,
T90, T120, T150, and T180 min post-injection. Experiment 6
included DBA/2J-Taar1+/+ KI and DBA/2J-Taar1m1J/m1J control
mice, tested at an average age of 92 ± 1 days, with a range of 62–
122 days. Experiment 7 included C57BL/6J-Taar1m1J/m1J KI and
C57BL/6J-Taar1+/+ control mice, tested at an average age of 82
± 1 days, with a range of 62–108 days.

Experiments 4 and 5: Two-Bottle Choice
Methamphetamine Intake in
DBA/2J-Taar1+/+ KI and
DBA/2J-Taar1m1J/m1J Control, and in
C57BL/6J-Taar1m1J/m1J KI and
C57BL/6J-Taar1+/+ Control Mice

Experiment 8: Morphine-Induced Body
Temperature Changes in MAHDR-Taar1+/+
KI and MAHDR-Taar1m1J/m1J Control Mice

A two-bottle choice MA vs. water drinking procedure, similar to
that used to characterize voluntary MA intake in our previous
studies was used (15–18). This study was conducted at JAX. One
day prior to testing, male and female mice were singly housed
and offered two water-filled 50 ml polypropylene centrifuge tubes
(item number 430291; Corning, Corning, NY) fitted with rubber
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Male and female MAHDR-Taar1+/+ KI and MAHDRTaar1m1J/m1J control mice were tested for sensitivity to the
hypothermic effect of 15 and 30 mg/kg morphine. These doses
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0.0001]. Female mice consumed more SACC than males (mean
± SEM = 106.6 ± 10.4 mg/kg vs. 77.9 ± 6.6 mg/kg, respectively),
and mice consumed more SACC when it was offered at the
higher concentration. These outcomes were not dependent on
mouse line. For SACC preference (Figure 1B) and total volume
consumed from the water plus SACC tubes (Figure 1C), there
were no significant effects of line, sex, or concentration.

were chosen from our previous research in the MADR lines (25).
This study was conducted at the VAPORHCS, and experimental
details were identical to those described for experiments 6 and 7.
Mice were tested at an average age of 85 ± 1 days, with a range of
65–109 days.

Statistics
Data were analyzed using factorial ANOVA with repeated
measures as appropriate. Independent grouping factors are
described with the results for each study. Complex interactions
involving more than 2 factors were first examined by 2-way
ANOVA at each level of the third factor. Significant 2-way
interactions were examined for simple main effects and means
were compared using the Newman–Keuls post-hoc test. The
number of post-hoc comparisons was reduced by assessing
changes from one mean to the next for concentration, time, and
trial effects, or between first and subsequent trials.

QUIN Intake, Preference, and Total Volume
Consumed
MAHDR-Taar1+/+ KI mice consumed more QUIN and had
a higher QUIN preference ratio, compared to MAHDRTaar1m1J/m1J control mice. The initial analysis of QUIN
intake data (Figure 1D) identified a significant line x QUIN
concentration interaction [F (1,44) = 13.9, p = 0.0005]. There were
no effects of sex. Follow-up analyses indicated that more QUIN
was consumed by mice of both lines when the concentration was
increased. The lines consumed comparable amounts of QUIN
at the lower concentration, but MAHDR-Taar1+/+ KI mice
consumed more QUIN than MAHDR-Taar1m1J/m1J control mice
when the QUIN concentration was increased (p = 0.001). For
QUIN preference (Figure 1E), there was a significant main effect
of line [F (1,44) = 6.2, p = 0.02], with MAHDR-Taar1+/+ KI
mice exhibiting higher preference than MAHDR-Taar1m1J/m1J
control mice. For total volume consumed (Figure 1F), there was
a significant line x concentration interaction [F (1,44) = 11.6, p =
0.001] that was associated with smaller volumes consumed by
MAHDR-Taar1+/+ KI mice when the lower vs. higher QUIN
concentration was offered (p < 0.0001; 4.9 ± 0.2 vs. 5.8 ± 0.2 for
the 0.015 and 0.03 mM concentrations, respectively). However,
there were no significant differences between the lines in total
volume consumed at either concentration.

RESULTS
Baseline Data
Baseline body weight data collected across studies, along with
age ranges, are summarized in Table 1. Although there were
some significant differences between genotypes in baseline body
weight, differences were not consistently found across studies,
suggesting that they were specific to the particular groups
of animals included in a given experiment. Thus, C57BL/6JTaar1m1J/m1J KI and C57BL/6J-Taar1+/+ control mice had
equivalent body weights in both studies in which they were
tested; DBA/2J-Taar1+/+ KI and DBA/2J-Taar1m1J/m1J control
mice differed in body weight in one, but not the other experiment;
and MAHDR-Taar1+/+ KI and MAHDR-Taar1m1J/m1J control
mice had comparable body weights in two studies and differed
in the remaining two. When significant, mean differences ranged
from 1.1 to 2.2 g. Total volume of water consumed was recorded
prior to tastant access in Experiment 1 and there was no
significant difference between the genotypes (mean ± SEM =
5.8 ± 0.2 ml vs. 6.0 ± 0.2 ml for KI and Control, respectively).
Other measures, including total volume of fluid consumed,
baseline locomotor activity level, and baseline body temperature
are reported with the experiments during which these data
were collected.

Experiment 2: MA-Induced Conditioned
Place Preference Testing in
MAHDR-Taar1+/+ KI and
MAHDR-Taar1m1J/m1J Control Mice
Data analyses considered percent time spent on the drug-paired
floor during the pre-test, drug-free test and drug-present test,
as measures of initial floor type bias, preference for floor cues
induced by prior association with MA, and preference for MAassociated floor cues when tested during the associative state
(Figure 2A). Locomotor activity data collected during these tests
were also analyzed (Figure 2B). Data were analyzed by repeated
measures factorial ANOVA grouped on mouse line and sex, with
test day as the repeated measure.

Experiment 1: Novel Tastant Intake and
Preference in MAHDR-Taar1+/+ KI and
MAHDR-Taar1m1J/m1J Control Mice
Data for each tastant were analyzed separately by repeated
measures factorial ANOVA grouped on mouse line and sex, with
concentration as the repeated measure.

Place Preference
Floor cues were initially equally preferred, and MA induced a
conditioned preference in MAHDR-Taar1m1J/m1J control mice,
but not MAHDR-Taar1+/+ KI mice. There was a significant
line × test day interaction [F (2,184) = 3.54, p = 0.03], but
no significant effects of sex. For initial preference, there was
no significant difference between the lines for percent time
spent on the assigned drug-paired floor, and values were near
50%, indicating that the floor types were approximately equally
preferred before conditioning. For the drug-free preference test,

SACC Intake, Preference, and Total Volume
Consumed
MAHDR-Taar1+/+ KI and MAHDR-Taar1m1J/m1J control mice
did not differ in SACC intake or preference (calculated as ml from
tastant tube/total ml consumed). The initial analysis of SACC
intake data (Figure 1A) identified significant effects of sex [F (1,44)
= 4.7, p = 0.036] and SACC concentration [F (1,44) = 124.2, p <
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TABLE 1 | Body weight and age range data for each study.
Body weight (g ± SEM)
Exp number

Study description

Mouse model

Age range (days)

KI

Control

(1)

Tastant intake

(2)

Mouse line comparison

MAHDR-Taar1+/+ KI
vs. Control

77–87

25.1 ± 0.7

25.7 ± 0.7

KI = Control

MA conditioned place preference

MAHDR-Taar1+/+ KI
vs. Control

73–107

25.7 ±0.4

27.9 ± 0.4***

KI < Control

(3)

MA conditioned taste aversion

MAHDR-Taar1+/+ KI
vs. Control

82–112

26.8 ± 0.6

27.9 ± 0.6

KI = Control

(4)

MA intake

DBA/2J-Taar1+/+ KI
vs. Control

56–88

21.2 ± 0.7

20.5 ± 0.7

KI = Control

(5)

MA intake

C57BL/6J-Taar1m1J/m1J KI
vs. Control

55–88

23.0 ± 0.5

23.8 ± 0.3

KI = Control

(6)

MA body temperature

DBA/2J-Taar1+/+ KI
vs. Control

62–122

25.2 ± 0.4

27.0 ± 0.4**

KI < Control

(7)

MA body temperature

C57BL/6J-Taar1m1J/m1J KI
vs. Control

62–108

24.0 ± 0.2

23.9 ± 0.2

KI = Control

(8)

Morphine body temperature

MAHDR-Taar1+/+ KI
vs. Control

65–109

26.1 ± 0.3

27.1 ± 0.3*

KI < Control

Exp, experiment; g, gram; KI, knock-in; MA, methamphetamine; MAHDR, methamphetamine high drinking mice; SEM, standard error of the mean; Taar1+/+ , homozygous reference
trace amine-associated receptor 1 genotype; Taar1m1J/m1J , homozygous mutant trace amine-associated receptor 1 genotype; * p < 0.05, ** p < 0.01, *** p < 0.001 for the difference
between mouse lines.

Locomotor Activity During Conditioning

there was a significant difference between the lines (p = 0.02),
with the MAHDR-Taar1m1J/m1J controls spending more time on
the drug-paired floor than the MAHDR-Taar1+/+ KI mice. A
similar outcome was obtained for the drug-present preference
test, with MAHDR-Taar1m1J/m1J controls spending significantly
more time on the drug-paired floor than the MAHDR-Taar1+/+
KI mice (p = 0.007).
Evidence for MA-conditioned preference is indicated by a
difference between percent time on the initial test day vs.
the two post-conditioning preference test days. For MAHDRTaar1m1J/m1J control mice, there was a significant effect of test
day [F (2,94) = 21.4, p < 0.0001], and post-hoc mean comparisons
indicated that percent time was greater after MA conditioning
when mice were tested under both drug-free and drug-present
states (ps < 0.001). For MAHDR-Taar1+/+ KI mice, there was
no significant effect of test day; thus, there was no evidence for
MA-induced conditioned place preference in these mice.

Locomotor activity level data during saline and MA conditioning
trials were analyzed for sex, line, and conditioning trial effects.
For saline trial data (Figure 3A), there were significant effects
of sex [F (1,92) = 7.75, p = 0.007] and trial [F (5,460) = 10.58,
p < 0.0001]. Males were more active than females and activity
levels declined significantly from trial 1 to 2 (p < 0.001), and
were then stable. For MA trial data (Figure 3B), there were no
significant sex effects, but there was a significant line × trial
interaction [F (5,460) = 2.57, p = 0.026]. The mouse lines had
comparable activity levels after the first MA treatment, then
MAHDR-Taar1+/+ KI mice were more active than MAHDRTaar1m1J/m1J control mice on subsequent trials. Although there
was a significant effect of trial within each line (ps < 0.001),
significant sensitization to the locomotor stimulant effect of
MA was found after fewer treatments in MAHDR-Taar1+/+
KI mice.

Locomotor Activity During Preference Testing

Experiment 3: MA-Induced Conditioned
Taste Aversion Testing in MAHDR-Taar1+/+
KI and MAHDR-Taar1m1J/m1J Control Mice

There was a significant sex × test day interaction [F (2,184) = 3.42,
p = 0.03]. Activity levels were comparable for males and females
during the initial and drug-free preference tests, but males were
significantly more active than females during the drug-present
test (p = 0.03; 3,753 ± 119 and 3,319 ± 157 for males and
females, respectively). Sex differences were not dependent on
line, but there was a significant line x test day interaction
[F (2,184) = 5.49, p = 0.005]. Activity levels were comparable
between the two genotypes during the initial preference test. Both
genotypes increased their activity during the subsequent 2 tests
(all ps < 0.001), with the highest level of locomotion during the
drug-present test and greater activity in MAHDR-Taar1+/+ KI,
compared to MAHDR-Taar1m1J/m1J control mice (p = 0.02 and
0.053 on the drug-free and drug-present test day, respectively).
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MAHDR-Taar1+/+ KI mice, but not MAHDR-Taar1m1J/m1J
control mice, exhibited sensitivity to MA-induced conditioned
taste aversion (Figure 4). NaCl intake data were analyzed by
repeated measures factorial ANOVA grouped on mouse line,
sex, and treatment (saline or 2 mg/kg MA), with test trial
as the repeated measure. There was a significant three-way
interaction of line, treatment, and trial [F (4,176) = 14.73, p
< 0.0001], but no significant effect of sex. For the MAHDRTaar1m1J/m1J control mice, there was a significant effect of
trial [F (4,88) = 4.76, p = 0.002], but no effect of treatment;
rather than a conditioned reduction in NaCl intake, these
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FIGURE 1 | Novel saccharin and quinine tastant intake and preference in MAHDR-Taar1+/+ KI and MAHDR-Taar1m1J/m1J control mice. Shown are means ± SEM for
(A) saccharin consumed (mg/kg/24 h), (B) saccharin preference ratio (ml from saccharin tube/total ml consumed), (C) total volume (ml/24 h) consumed (water +
saccharin solution) during access to each saccharin concentration, (D) quinine consumed (mg/kg 24 h), (E) quinine preference ratio (ml from quinine tube/total ml
consumed), and (F) total volume consumed (water + quinine solution) during quinine access. Tastants were offered vs. water for 4-day periods at increasing
concentrations in counterbalanced order. Total N = 48 mice (12 mice per sex for the MAHDR-Taar1+/+ KI; 10 female MAHDR-Taar1m1J/m1J control mice, and 14 male
MAHDR-Taar1m1J/m1J control mice). *p < 0.05, **p < 0.01 for the main effect of mouse line (E) or for the line difference at the indicated concentration (D);
+++
p < 0.001 for the main effect of concentration (A) or for the concentration difference for the indicated mouse line (D,F). MAHDR, methamphetamine high drinking
mice; Taar1+/+ , homozygous reference trace amine-associated receptor 1 genotype; Taar1m1J/m1J , homozygous mutant trace amine-associated receptor 1 genotype.

interaction [F (4,88) = 34.4, p < 0.0001]; there was no significant
effect of trial for the saline treatment group, but there
was for the MA treatment group (p < 0.0001). Post-hoc
comparisons indicated that NaCl intake was lower for trials 2–5,

mice consumed significantly more NaCl during trials 3–
5, compared to trial 1 (p = 0.04, 0.04, and 0.0008, for
trials 3, 4, and 5, respectively; Figure 4A). For the MAHDRTaar1+/+ KI mice, there was a significant trial × treatment
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DBA/2J-Taar1+/+ KI mice (Figure 5). Average MA intake,
preference and total volume intake data were analyzed by
repeated measures factorial ANOVA grouped on mouse line, sex,
and MA concentration. For MA intake (Figure 5A), there was a
significant line × MA concentration interaction [F (3,78) = 5.9,
p = 0.001], but no effect of sex. DBA/2J-Taar1m1J/m1J control
mice consumed more MA than DBA/2J-Taar1+/+ KI mice at
all MA concentrations. Intake significantly increased as MA
concentration was increased for DBA/2J-Taar1m1J/m1J control
mice (ps < 0.0001), with a statistical trend for KI mice (p = 0.06);
results for mean comparisons are shown in Figure 5A.
For MA preference (Figure 5B), there was a main effect
of line [F (1,78) = 12.9, p = 0.001], with DBA/2J-Taar1m1J/m1J
control mice exhibiting a greater MA preference ratio, compared
to DBA/2J-Taar1+/+ KI mice. There was also a significant
main effect of concentration [F (3,78) = 5.8, p = 0.001];
preference declined with increasing concentration. For total
volume consumed (Figure 5C), the only significant effect was
MA concentration [F (3,84) = 7.7, p = 0.0001]; total volume
increased with increasing MA concentration.

Experiment 5: Two-Bottle Choice
Methamphetamine Intake in
C57BL/6J-Taar1m1J/m1J KI and
C57BL/6J-Taar1+/+ Control Mice
C57BL/6J-Taar1m1J/m1J KI mice consumed more MA and
exhibited greater MA preference than C57BL/6J-Taar1+/+
control mice (Figure 6). MA intake, preference and total volume
intake data were analyzed as described for Experiment 4. For MA
intake (Figure 6A), there was a significant line x concentration
interaction [F (3,129) = 19.4, p < 0.0001]. C57BL/6J-Taar1m1J/m1J
KI mice consumed more MA than C57BL/6J-Taar1+/+ control
mice at all MA concentrations, except 10 mg/L (there was a strong
statistical trend, p = 0.07). Although there was an increase in
intake in both lines across concentration, the increase was steeper
in the C57BL/6J-Taar1m1J/m1J KI mice (see mean comparison
results in Figure 6A). There was also a significant line x sex
interaction [F (1,129) = 5.4, p = 0.025]. However, this interaction
was due to a magnitude effect, as there was a significant difference
in MA intake between the KI and control mice (ps < 0.001) for
both males and females (5.2 ± 0.6 mg/kg and 2.7 ± 0.4 for KI vs.
control males; 7.5 ± 0.6 and 2.5 ± 0.4 for KI vs. control females),
but the difference was 1.9 fold in males and 3 fold in females.
For MA preference (Figure 6B), there was a significant line ×
concentration interaction [F (3,132) = 5.5, p = 0.001], with
significantly greater MA preference in C57BL/6J-Taar1m1J/m1J
KI mice compared to C57BL/6J-Taar1+/+ control mice for
the 40 and 80 mg/L concentrations (ps < 0.001). There was
no significant effect of sex. MA preference decreased in the
control mice across increasing concentrations (p < 0.0001;
see Figure 6B for mean comparisons), but remained stable in
the KI mice. For total volume consumed (Figure 6C), there
was a significant line × sex interaction [F (1,44) = 13.9, p =
0.0006], and a significant effect of concentration [F (3,129) =
3.3, p = 0.02]. However, there were no significant increases in
fluid consumption from one concentration to the next higher

FIGURE 2 | MAHDR-Taar1m1J/m1J control mice, but not MAHDR-Taar1+/+ KI
mice, exhibit MA-induced conditioned place preference and are less active
during preference testing. Shown are means ± SEM for (A) percent time on
drug-paired floor during the pre-test, drug-free test, and drug-present test and
for (B) locomotor activity counts during the three tests. Mice were treated with
saline prior to preference testing for the pre-test and drug-free test, and with
0.5 mg/kg MA prior to the drug-present test; tests were 30 min in duration.
Total N = 96 mice (12 mice per line per sex were conditioned with MA on the
grid floor; 12 mice per line per sex were conditioned with MA on the hole floor).
*p ≤ 0.05, **p < 0.01 for the line difference; +++ p < 0.001 for the difference
from pre-test in (A) and for the difference from pre-test and drug-free or
drug-present test in (B). MA, methamphetamine; MAHDR, methamphetamine
high drinking mice; Taar1+/+ , homozygous reference trace amine-associated
receptor 1 genotype; Taar1m1J/m1J , homozygous mutant trace
amine-associated receptor 1 genotype.

compared to trial 1 (all ps < 0.001; Figure 4B), supporting
the development of a conditioned taste aversion in MAHDRTaar1+/+ KI mice.

Experiment 4: Two-Bottle Choice
Methamphetamine Intake in
DBA/2J-Taar1+/+ KI and
DBA/2J-Taar1m1J/m1J Control Mice
DBA/2J-Taar1m1J/m1J control mice consumed more MA
and exhibited greater MA preference, compared to
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FIGURE 3 | Locomotor activity levels of saline-treated and acute MA-treated MAHDR-Taar1+/+ KI and MAHDR-Taar1m1J/m1J control mice are comparable, but
locomotor sensitization is more rapid in MAHDR-Taar1+/+ KI mice. Shown are mean ± SEM locomotor activity counts on each day of conditioning with either (A)
saline or (B) MA. Mice were treated with saline or 0.5 mg/kg MA immediately prior to each 15-min conditioning trial. Mice were the same animals that generated the
data in Figure 2. *p < 0.05, **p < 0.01 for the line difference; ++ p < 0.01, +++ p < 0.001 for the difference from the previous conditioning trial. MA,
methamphetamine; MAHDR, methamphetamine high drinking mice; Taar1+/+ , homozygous reference trace amine-associated receptor 1 genotype; Taar1m1J/m1J ,
homozygous mutant trace amine-associated receptor 1 genotype.

(27.6 ± 1.2 vs. 22.0 ± 0.9, respectively; p = 0.0004), but no
significant difference between male mice of the KI and control
lines (22.7 ± 1.2 vs. 24.7 ± 0.8, respectively; p = 0.17).

Experiment 6: MA-Induced Body
Temperature Change in DBA/2J-Taar1+/+
KI and DBA/2J-Taar1m1J/m1J Control Mice
DBA/2J-Taar1+/+ KI mice displayed MA-induced hypothermia,
whereas DBA/2J-Taar1m1J/m1J control mice exhibited MAinduced hyperthermia (Figure 7). An interaction with sex was
associated with a longer duration of the difference in body
temperature response between the two lines in females than in
males. Thus, the sex difference did not impact the conclusion
regarding the impact of the genetic manipulation. The following
analyses support our conclusions. Body temperature data were
first analyzed by repeated measures factorial ANOVA grouped
on line, sex and treatment (saline or 2 mg/kg MA), with
time as the repeated measure. There was a significant fourway interaction [F (5,365) = 4.3, p = 0.0009]. Because our
main interest is in differences between the mouse lines in
MA response, we performed ANOVAs to determine if there
were effects of line, treatment and time within each sex. In
both the males and females, there was a significant line ×
treatment × time interaction [F (5,180) = 6.4, p < 0.0001 for
males; F (5,185) = 11.3, p < 0.0001 for females]. For both male
and female DBA/2J-Taar1m1J/m1J control mice, there was a
treatment × time interaction [F (5,90) = 7.1, p < 0.0001 for
males; F (5,95) = 9.2, p < 0.0001 for females]. Mean differences
are indicated in Figures 7A,B. There were no differences
in body temperature between the treatment groups at T0.
Female DBA/2J-Taar1m1J/m1J control mice treated with MA had

FIGURE 4 | MAHDR-Taar1+/+ KI mice, but not MAHDR-Taar1m1J/m1J control
mice, exhibit MA-induced conditioned taste aversion. Shown are means ±
SEM for 0.2 M NaCl intake in (A) MAHDR-Taar1m1J/m1J control mice and (B)
MAHDR-Taar1+/+ KI mice. Consumption trials were separated by 48 h, and
saline or 2 mg/kg MA injections (IP) were given immediately after 1 h NaCl
access for trials 1–4. Total N = 48 mice (6 per line per sex per treatment).
***p < 0.001 for the difference between treatment groups; + p < 0.05,
+++
p < 0.001 for the difference compared to trial 1, collapsed on treatment
(A) or within the MA treatment group (B). MA, methamphetamine; MAHDR,
methamphetamine high drinking mice; NaCl, sodium chloride;
Taar1+/+ , homozygous reference trace amine-associated receptor 1
genotype; Taar1m1J/m1J , homozygous mutant trace amine-associated
receptor 1 genotype.

concentration. The line × sex interaction was due to significantly
more total volume consumed by female C57BL/6J-Taar1m1J/m1J
KI mice, compared to female C57BL/6J-Taar1+/+ control mice
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FIGURE 5 | DBA/2J-Taar1m1J/m1J control mice consume more MA and exhibit
greater MA preference, compared to DBA/2J-Taar1+/+ KI mice. Shown are
means ± SEM for (A) average MA consumed (mg/kg/24 h), (B) preference
ratio (ml from MA tube/total ml consumed), and (C) total volume consumed
(ml/24 h) during two-bottle choice of water and ascending concentrations of
MA. Each concentration was offered for a 4-day period. Total N = 32 mice
(eight per mouse line per sex); *p < 0.05, **p < 0.01, ***p < 0.001 for the
difference between mouse lines for a given concentration (A) or collapsed on
concentration (B); ++ p < 0.01, +++ p < 0.001 for the effect of concentration
compared to the previous concentration (A) or for the main effect of
concentration (B,C). MA, methamphetamine; Taar1+/+ , homozygous
reference trace amine-associated receptor 1 genotype; Taar1m1J/m1J ,
homozygous mutant trace amine-associated receptor 1 genotype.

FIGURE 6 | C57BL/6J-Taar1m1J/m1J KI mice consume more MA and exhibit
greater MA preference than C57BL/6J-Taar1+/+ control mice. Shown are
means ± SEM for (A) average MA consumed (mg/kg/24 h), (B) preference
ratio (ml from MA tube/total ml consumed), and (C) total volume consumed
(ml/24 h) during two-bottle choice of water and ascending concentrations of
MA. Each concentration was offered for a 4-day period. Total N = 47 (eight
mice per sex for the C57BL/6J-Taar1m1J/m1J KI; 16 male C57BL/6J-Taar1+/+
control mice, and 15 female C57BL/6J-Taar1+/+ control mice. **p < 0.01,
***p < 0.001 for the difference between mouse lines; + p < 0.05, ++ p < 0.01,
+++
p < 0.001 for the effect of concentration compared to the previous
concentration (A,B) or for the main effect of concentration (C). MA,
methamphetamine; Taar1+/+ , homozygous reference trace amine-associated
receptor 1 genotype; Taar1m1J/m1J , homozygous mutant trace
amine-associated receptor 1 genotype.

significantly higher body temperatures at T30–T180 than their
saline-treated counterparts. A similar difference was found in
males, beginning at T60. For both male and female DBA/2JTaar1+/+ KI mice, there was a treatment × time interaction
[F (5,90) = 18.9, p < 0.0001 for males; F (5,90) = 8.8, p < 0.0001 for
females]. Mean differences are indicated in Figures 7C,D. There
were no differences in body temperature between the treatment
groups at T0. Female DBA/2J-Taar1+/+ KI mice exhibited longlasting hypothermia from T30-T120, whereas males exhibited
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significant MA-induced hypothermia only at T30. The MAtreated males had significantly higher body temperatures than
saline-treated males at T120 and T180.
We next examined the data for line, sex and time differences
within each treatment condition. Data are presented in
Supplementary Figure 1. For the saline-treated mice, there was
a significant effect of time [F (5,185) = 18.9, p < 0.0001], but
no significant effect of line or sex. Body temperature changes
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FIGURE 8 | C57BL/6J-Taar1m1J/m1J KI mice display MA-induced
hyperthermia, whereas C57BL/6J-Taar1+/+ control mice exhibit MA-induced
hypothermia. Shown are means ± SEM for core body temperature (◦ C) for
(A) C57BL/6J-Taar1+/+ control and (B) C57BL/6J-Taar1m1J/m1J KI mice.
A baseline temperature was obtained (T0), mice were treated IP with saline or
2 mg/kg MA, and then rectal temperatures were obtained periodically
from T30 to T180. Total N = 98 (11 female and 13 male saline-treated
C57BL/6J-Taar1+/+ control; 11 female and 12 male MA-treated
C57BL/6J-Taar1+/+ control; 13 saline-treated C57BL/6J-Taar1m1J/m1J KI
per sex; 12 female and 13 male MA-treated C57BL/6J-Taar1m1J/m1J KI).
***p < 0.001 for the effect of treatment; + p < 0.05, ++ p < 0.01,
+++
p < 0.001 for the change in body temperature from the previous
temperature. MA, methamphetamine; Taar1+/+ , homozygous reference trace
amine-associated receptor 1 genotype; Taar1m1J/m1J , homozygous mutant
trace amine-associated receptor 1 genotype.

FIGURE 7 | DBA/2J-Taar1+/+ KI mice display MA-induced hypothermia,
whereas DBA/2J-Taar1m1J/m1J control mice exhibit MA-induced hyperthermia.
Shown are means ± SEM for core body temperature (◦ C) for female (A) and
male (B) DBA/2J-Taar1m1J/m1J control mice, and for female (C) and male (D)
DBA/2J-Taar1+/+ KI mice. Data are shown separately for the sexes due to a
significant line × sex × treatment interaction. A baseline temperature was
obtained (T0), mice were treated IP with saline or 2 mg/kg MA, and then rectal
temperatures were obtained periodically from T30 to T180. Total N = 81 mice
(11 female saline and 10 female MA-treated DBA/2J-Taar1m1J/m1J control; 10
female DBA/2J-Taar1+/+ KI per treatment; 10 male per mouse line and
treatment). *p < 0.05, **p < 0.01, ***p < 0.001 for the effect of treatment;
+
p < 0.05, ++ p < 0.01, +++ p < 0.001 for the change in body temperature
from the previous temperature. MA, methamphetamine; Taar1+/+ ,
homozygous reference trace amine-associated receptor 1 genotype;
Taar1m1J/m1J , homozygous mutant trace amine-associated receptor 1
genotype.

exhibited MA-induced hypothermia (Figure 8). The following
analyses support this summary. Body temperature data were
first analyzed by repeated measures factorial ANOVA grouped
on line, sex, and treatment (saline or 2 mg/kg MA), with time
as the repeated measure. There were two significant three-way
interactions; a line × treatment × time interaction [F (5,450) =
20.0, p < 0.0001] and a sex × treatment × time interaction
[F (5,450) = 7.0, p < 0.0001]. There were no interactions of sex
with line, indicating that line differences were not sex-dependent.
To examine the line × treatment × time interaction, data
were examined for treatment effects within each line. For
the C57BL/6J-Taar1+/+ control mice (Figure 8A), there was a
significant treatment × time interaction [F (5,225) = 34.7, p <
0.0001]. MA produced significant hypothermia at T30, and the
declining temperatures that occurred in the saline group across
time were reduced in the MA-treated mice; thus, they had higher
body temperatures at T90–T180. For the C57BL/6J-Taar1m1J/m1J
KI mice (Figure 8B), there was a significant treatment × time
interaction [F (5,245) = 37.2, p < 0.0001]. MA-treated mice had
higher body temperatures than saline-treated mice at all time
points except T0.
We next examined the data for line and time differences
within each treatment condition. Data are presented in
Supplementary Figure 2. For the saline group, there was a
significant effect of time [F (5,240) = 140.8, p < 0.0001], but
no body temperature differences between the mouse lines.
For the MA treatment group, there was a significant line ×
time interaction [F (5,230) = 23.0, p < 0.0001], and the mouse
lines differed in body temperature at all time points except

were examined by comparing adjacent means (i.e., change
from the prior time point). Body temperature at T180 was
significantly lower than at T120 (p < 0.0001). For the MAtreated mice, there was a significant 3-way interaction of line, sex
and time [F (5,180) = 3.8, p = 0.003). There were no differences
in body temperature between the lines for the MA-treatment
group at T0. Female DBA/2J-Taar1+/+ KI mice had lower
body temperatures than female DBA/2J-Taar1m1J/m1J control
mice after MA treatment at T30–T180. A similar difference was
found in males at T30–T90. Significant changes across time are
indicated in Supplementary Figure 1.

Experiment 7: MA-Induced Body
Temperature Change in
C57BL/6J-Taar1m1J/m1J KI and
C57BL/6J-Taar1+/+ Control Mice
C57BL/6J-Taar1m1J/m1J KI mice displayed MA-induced
hyperthermia, whereas C57BL/6J-Taar1+/+ control mice
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T0 and T180. Significant changes across time are indicated in
Supplementary Figure 2.

Experiment 8: Morphine-Induced Body
Temperature Changes in MAHDR-Taar1+/+
KI and MAHDR-Taar1m1J/m1J Control Mice
MAHDR-Taar1+/+ KI and MAHDR-Taar1m1J/m1J control
mice, exhibited comparable sensitivity to morphine-induced
hypothermia (Figure 9). The following statistical outcomes
support this conclusion. In the initial 4-way repeated measures
ANOVA, the only significant effects involving line were line x
morphine dose [F (2,129) = 3.2, p = 0.04] and line × time [F (5,645)
= 3.6, p = 0.003] interactions. However, further examination
of the effect of line at each morphine dose, identified no
statistically significant differences, and examination of the line ×
time interaction identified a significant line difference in body
temperature only at T0 (p < 0.0001), with a higher temperature
in MAHDR-Taar1+/+ KI than MAHDR-Taar1m1J/m1J control
mice of only 0.4◦ C. Although line did not interact with morphine
dose and time, data were analyzed separately for each line to
demonstrate that morphine induced significant hypothermia.
The outcomes of these analyses are represented in Figures 9A,B.
Within each line, there was no effect of dose at T0, but there
were significant dose effects at all other time points, supporting
morphine-induced hypothermia.
In addition, there was a sex × treatment × time interaction
[F (10,645) = 2.2, p = 0.02]. When data were examined for sex
differences, there was a significant sex × time interaction for
the 0 [F (5,220) = 2.6, p = 0.03] and 30 mg/kg [F (5,225) =
3.8, p = 0.002] dose groups, but not the 15 mg/kg dose
group. Further examination of the effect of sex at each time
point for the saline treatment dose, identified no statistically
significant differences. For the 30 mg/kg dose group, females
had lower temperatures than males at T30 (p = 0.004)
and T60 (p = 0.03), reflecting greater morphine-induced
hypothermia. The temperature difference was 1.2◦ C at T30
and 1.3◦ C at T60; however, this sex effect was not dependent
on line and thus, did not impact conclusions regarding the
genetic manipulation.

FIGURE 9 | MAHDR-Taar1+/+ KI and MAHDR-Taar1m1J/m1J control mice,
exhibited comparable sensitivity to morphine-induced hypothermia. Shown are
means ± SEM for core body temperature (◦ C) for (A) MAHDR-Taar1m1J/m1J
control and (B) MAHDR-Taar1+/+ KI mice. A baseline temperature was
obtained (T0), mice were treated IP with saline, 15 or 30 mg/kg morphine, and
then rectal temperatures were obtained periodically from T30 to T180. Total
N = 140 mice (11 saline-treated MAHDR-Taar1+/+ KI per sex; 12, 15 mg/kg
morphine-treated MAHDR-Taar1+/+ KI per sex; 11 male and 12 female 30
mg/kg morphine-treated MAHDR-Taar1+/+ KI; 12 MAHDR-Taar1m1J/m1J
control mice per dose per sex). **p < 0.01; ***p < 0.001 for the effect of
treatment; + p < 0.05, ++ p < 0.01, +++ p < 0.001 for the change in body
temperature from the previous temperature. MA, methamphetamine; MAHDR,
methamphetamine high drinking mice; Taar1+/+ , homozygous reference trace
amine-associated receptor 1 genotype; Taar1m1J/m1J , homozygous mutant
trace amine-associated receptor 1 genotype.

DISCUSSION
Our research provides new and conclusive evidence indicating
that a Taar1 SNP with a key role in MA intake also
impacts sensitivity to MA-induced conditioned place preference,
conditioned taste aversion and hypothermia. Furthermore, we
demonstrate impacts of Taar1 genotype on multiple genetic
backgrounds and significant reciprocal effects of allele exchange
by CRISPR-Cas9. Low MA intake is associated with low
sensitivity to MA reward and high sensitivity to aversive
effects of MA. Furthermore, we confirm prior evidence
indicating that a gene in linkage disequilibrium with Taar1 is
responsible for a difference in sensitivity to morphine-induced
hypothermia in the MADR mouse lines. Table 2 summarizes our
key findings.

Frontiers in Psychiatry | www.frontiersin.org

Pleiotropic Effects of Taar1 on MA-Related
Traits in MAHDR Mice
MAHDR mice were selectively bred for high levels of voluntary
MA intake using a two-bottle choice water vs. MA solution
procedure. Subsequent investigation established that taste does
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32). When we examined Taar1 and Oprm1 genotype in MADR
line mice tested for morphine-induced hypothermia, there was
correspondence of magnitude of hypothermia with Oprm1, but
not Taar1, genotype (25). The current data in the MAHDR
KI model are consistent with the conclusion that the Taar1
SNP is not responsible for the difference in morphine-induced
hypothermia between the MADR lines, and that another gene(s)
is responsible. We have not tested the MAHDR KI mice for
all of the traits previously examined in the MADR lines, but
would not expect the KI and control lines to differ for cocaine or
alcohol responses. We did observe an unexpected difference in
quinine intake in experiment 1, but it was the MA-avoiding line
that consumed more quinine, so this result does not provide an
explanation for higher consumption of bitter-tasting MA. Future
studies will track the reliability of this outcome by repeating the
study in all of the KI models.
Finally, the results for locomotor activity in the MAHDR KI
and control mice agree with our prior findings in the MADR
lines that also did not differ in acute locomotor response to 0.5
mg/kg MA. However, the differences found here between the
lines, with Taar1+/+ mice exhibiting greater locomotor activity
on subsequent MA treatment trials than Taar1m1J/m1J mice, were
not found for the MALDR and MAHDR lines (16). Although it is
possible that this difference is related to Taar1 genotype, existing
studies indicate that mice without Taar1 function would be
more likely to exhibit the greater stimulant response (see section
Other examples of single gene identification for addiction-related
traits), opposite to our finding. However, differences in those
studies were found for higher doses of MA. It is possible that
a genetic background difference played a role in the current
outcome. Dose-response studies and studies in the other KI and
control lines would benefit interpretation.

TABLE 2 | Summary of results for Taar1 genotype effects for all experiments.
Trait

(1)

Intake

MAHDR

SACC, 1.6 and 3.2 mM

=

Preference

MAHDR

SACC, 1.6 and 3.2 mM

=

Total volume MAHDR

SACC, 1.6 and 3.2 mM

=

Intake

MAHDR

QUIN, 0.015 and 0.03 mM

≥

Preference

MAHDR

QUIN, 0.015 and 0.03 mM

>

(1)

Background Tastant or Drug, Dose
or Conc.

Taar1+/+ vs.
Taar m1J/m1J

Exp

Total volume MAHDR

QUIN, 0.015 and 0.03 mM

=

CPP baseline MAHDR

Saline

=

CPP
drug-free

MAHDR

MA, 0.5 mg/kg then saline
test

<

CPP drugpresent

MAHDR

MA, 0.5 mg/kg then 0.5
mg/kg test

<

(3)

CTA

MAHDR

MA, 0 and 2 mg/kg

>

(4)

Intake

DBA/2J

MA, 10–80 mg/L

<

Preference

DBA/2J

MA, 10–80 mg/L

<

Total volume DBA/2J

MA, 10–80 mg/L

=

Intake

C57BL/6J

MA, 10–80 mg/L

<

Preference

C57BL/6J

MA, 10–80 mg/L

<

Total volume C57BL/6J

MA, 10–80 mg/L

<*

Hypothermia DBA/2J

MA, 0 and 2 mg/kg

>

Hyperthermia DBA/2J

MA, 0 and 2 mg/kg

<

Hypothermia C57BL/6J

MA, 0 and 2 mg/kg

>

Hyperthermia C57BL/6J

MA, 0 and 2 mg/kg

<

Hypothermia MAHDR

Morphine, 0, 15, and
30 mg/kg

=

(2)

(5)

(6)
(7)
(8)

* This

difference was found in females only; Conc., concentration; CPP, conditioned place
preference; CTA, conditioned taste aversion; Exp, experiment; MA, methamphetamine;
MAHDR, methamphetamine high drinking line; QUIN, quinine; SACC, saccharin;
Taar1+/+ , homozygous reference trace amine-associated receptor 1 genotype;
Taar1m1J/m1J , homozygous mutant trace amine-associated receptor 1 genotype.

Genetic Background Effects
Previous data support an impact of Taar1 genotype on
MA intake and other MA-related traits in multiple mouse
models, derived from the DBA/2J and C57BL/6 strains that
served as the progenitors of the MADR lines (22). Because
many polymorphisms differentiate these strains, more definitive
attribution of a trait difference to the Taar1 SNP is provided
by KI models in which the SNP is specifically manipulated.
Thus, we generated multiple CRISPR-Cas9 KI models to provide
conclusive evidence of the impact of the Taar1 SNP and examine
potential genetic background effects. In addition, robust effects
were observed when the mutant Taar1 allele was replaced with
the reference allele in MAHDR mice (21), but we did not
know whether such robust effects would be observed for the
reciprocal manipulation. Results for MA intake and preference
aligned with Taar1 genotype across all of the KI models. Thus,
Taar1m1J/m1J mice of both MAHDR and DBA/2J backgrounds
consumed more MA and exhibited greater MA preference than
their Taar1+/+ controls [see (21) and Table 2]. Likewise, results
for MA treatment-induced temperature changes were aligned
with Taar1 genotype across all of the KI models, with Taar1+/+
controls exhibiting hypothermic responses that did not occur in
Taar1m1J/m1J mice [see (20) and Table 2].

not provide an explanation for the difference in MA intake
between the MADR lines (16, 18), the MAHDR mice will
voluntarily consume binge-like levels of MA (17), and baseline
measures, including locomotor activity, measures of learning
and memory, body weight, and body temperature, do not
systematically differentiate the lines (26). Furthermore, the lines
do not differ in responses to cocaine or alcohol, but they do differ
in responses to fentanyl, morphine and amphetamine-like drugs,
including MDMA (25, 28–30). The current studies investigated
whether the Taar1 SNP that impacts MA intake also plays a
part in the reliable differences in MA-induced conditioned place
preference, conditioned taste aversion and hypothermia we have
observed between the MADR lines (16, 18, 20, 27). Our results
confirm an impact of this polymorphism on all three traits.
MAHDR mice consume less morphine and exhibit greater
morphine-induced hypothermia than MALDR mice (25, 28).
Both Taar1 and the µ-opioid receptor gene, Oprm1, are on
mouse chromosome 10, 17 Mb apart. We speculated that the
differences in morphine consumption and hypothermia were
associated with linkage disequilibrium and more likely an effect
of different Oprm1 alleles inherited from the DBA/2J and
C57BL/6J strains, known to impact morphine preference (31,
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Other Examples of Single Gene
Identification for Addiction-Related Traits

Although there were similar general outcomes, there were
some qualitative differences in results across the models.
Because MA intake data for the DBA/2J and C57BL/6 genetic
backgrounds were not collected simultaneously, they could
not be subjected to direct comparative analysis, but some
observations may be worth noting. The effect of exchanging the
reference Taar1 allele with the mutant allele in C57BL/6J mice
was an increase in MA intake that peaked at about 14 mg/kg
for the 80 mg/L MA concentration, whereas the DBA/2J mice,
which naturally possess the mutant Taar1 genotype consumed
about 10 mg/kg MA at the 80 mg/L concentration. Furthermore,
the MA intake of mice possessing the Taar1+/+ genotype on
the C57BL/6J vs. DBA/2J background was 5 mg/kg, compared to
3 mg/kg, for the highest MA concentration. This may indicate
that there are other genetic variants promoting MA intake in
the C57BL/6J strain even in the presence of the protective
Taar1+/+ genotype. This is supported by somewhat higher
MA preference in Taar1+/+ mice of the C57BL/6J background.
However, the lower overall MA preference of mice with the
Taar1+/+ genotype, compared to those with the Taar1m1J/m1J
genotype, was clear on both backgrounds. In previous studies,
results were compared under identical conditions for DBA/2J
and MAHDR mice for MA intake in a binge drinking procedure
and for the effect of binge-level drinking followed by withdrawal
on depression-like outcomes. MAHDR mice consumed almost
twice as much MA as DBA/2J mice. In addition, MAHDR mice
displayed greater depression-like symptoms after withdrawal,
which may have been related to their higher MA intake (33).
Higher MA intake of the MAHDR mice, compared to the
DBA/2J, could be due to the presence of C57BL/6J alleles in the
MAHDR mice that are permissive for MA intake.
Another apparent difference found in the current studies
was a greater reduction over time in body temperature of
saline-treated C57BL/6J mice, compared to DBA/2J mice, during
isolate housing. This did not impact our ability to detect MAinduced hypothermia, because that effect tends to be most
robust within the first 30 min after administration, but it did
clearly demonstrate the ability of MA treatment to inhibit the
progressive reduction in body temperature.
Rarely have we found sex differences that interact with line in
our previous studies of MA-related traits. A significant line × sex
× time interaction was observed in the examination of MA effects
on body temperature in the DBA/2J KI and control line study, but
not the C57BL/6J study. Examination of the patterns of response
in Figures 7, 8 indicate a strong similarity in male DBA/2J mice
with the overall outcome for the C57BL/6J mice. However, female
DBA-Taar1+/+ KI mice had a markedly prolonged hypothermic
response to the 2 mg/kg dose of MA that is more reminiscent
of our previous data in MALDR mice (20) and the MAHDRTaar1+/+ KI mice (21), although sex differences were not found
in those studies. We have speculated that greater sensitivity
to hypothermic drug effects may be protective against further
drug intake and drug toxicity, and could serve as a marker for
reduced psychostimulant addiction risk (25, 34, 35). Additional
data are needed to determine if this is a replicable finding
worth pursuing.

Frontiers in Psychiatry | www.frontiersin.org

The successful identification of single gene effects on complex
traits, including addiction-related phenotypes, is increasing.
Drug-induced stimulation has been of considerable focus,
because feelings of stimulation or euphoria in humans appear
to contribute to the potential for escalated use (36). Recent data
confirmed Hnrnph1 as a quantitative trait gene for sensitivity to
MA-induced stimulation (37). Similar to the way in which Taar1
was identified, Hnrnph1 was first implicated in a quantitative
trait locus analysis (38), and then gene editing was used to
produce a deletion in the first coding exon of the gene and
substantiate its role. Not only did this deletion reduce sensitivity
to MA stimulation, it also decreased MA-induced reinforcement,
reward and dopamine release (39). It is of interest that MAinduced stimulation also tends to be greater in Taar1m1J/m1J
and Taar1 knock-out mice, both of which lack TAAR1 function
and consume more MA or exhibit greater MA reward and
reinforcement (16, 18, 20, 40–43). Another study focused on a
region of the cannabinoid-1 receptor gene associated with drug
and alcohol addiction (44, 45). Deletion using CRISPR-Cas9
technology reduced expression of the cannabinoid-1 receptor
in the hippocampus and also reduced alcohol intake (46).
Thus, in recent years, several addiction-relevant genes have
been identified using genetic mapping and rapid deletion and
KI techniques.
The Taar1 SNP is a spontaneously occurring mutation that
arose in the JAX DBA/2J mice between 2001 and 2003 (22). Such
mutations are not rare. For example, a single base pair deletion
arose in intron 3 of the C57BL/6J Gabra2 gene adjacent to a
splice acceptor site that results in global reduction of mRNA
and protein level expression, compared to levels found in other
inbred mouse strains. When CRISPR-Cas9 was used to repair the
deletion, mRNA and protein levels were restored (47). GABRA2
variation has been implicated in alcoholism and drug abuse in
human populations (48–52). It is possible that this gene also plays
a role in the high alcohol consumption found in C57BL/6J mice,
compared to many other strains [e.g., (53, 54)].
Finally, based on previous data supporting an association
of the glutamate receptor subunit gene, ionotropic N-methyld-aspartate 3A (GRIN3A), with nicotine dependence, 16 SNPs
were examined in a Chinese Han population. A single SNP
association was identified and gene editing was performed in
cultured cells using CRISPR-Cas9 to demonstrate a regulatory
function impacting mRNA and protein expression that could
be related to differential susceptibility to nicotine dependence
(55). The obvious question arises as to whether human TAAR1
variants impact risk for MA addiction. In the mouse, a key
feature of Taar1 involvement in MA intake appears to be initial
sensitivity to adverse effects of MA, such as conditioned aversion
and hypothermia. In fact, the MALDR mice bred for low MA
intake consume a comparable amount the first time MA is
offered, precipitously reducing their intake in the next drinking
session, presumably after experiencing negative subjective effects
(42, 56). The predictive outcome of negative first experiences
with amphetamines have not often been studied in humans,
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possible Taar1 genotypes: Taar1+/+ , Taar1+/m1J , Taar1m1J/m1J .
Taar1 genotype—phenotype correlations for MA intake in F2
mice, raised with mixed Taar1 genotypes among littermates, are
comparable to those for MADR line individuals and BXD RI
strains (22).

although there are a few laboratory-based studies. The general
outcome for acute amphetamine and methylphenidate, the two
drugs most studied in healthy non-addicted young adults, have
documented variation in ratings of arousal, liking and anxiety.
Most report positive mood effects, but some report unpleasant
effects, and these outcomes predict subsequent session choices
of whether or not to take the drug again [see (36)]. None of
this research has examined genetic relationships. A recent study
by Loftis et al. (57) identified a synonymous TAAR1 SNP that
was associated with higher MA craving in individuals with active
MA dependence and in remission, compared to controls with no
history of substance dependence. When examined in cell culture,
cells transfected with this variant had 40% higher TAAR1 protein
expression, compared to cells transfected with the wild-type
allele, but no change in protein function. It would be interesting
to test this variant in a rodent model of MA craving.

CONCLUSIONS AND FUTURE
DIRECTIONS
The Taar1 SNP at position 229 accounts for 60% of the genetic
variance in MA intake in the selectively bred MADR lines
(19, 21). Additional research is underway to identify other
genes that impact MA intake, including the identification of
relevant gene networks [e.g., (15, 19)]. Variance in MA intake
in mice with functional TAAR1 is low, whereas variance in
mice lacking TAAR1 function is high (17, 22). Data herein and
in our published papers indicate that TAAR1 agonist effects
of MA are aversive, and we hypothesize that these effects
mask rewarding MA effects, strongly inhibiting MA intake.
Greater knowledge about the mechanisms by which TAAR1
agonism induces aversion could be leveraged to identify more
efficacious treatments for methamphetamine addiction. Because
TAAR1 is located intracellularly, MA must be transported into
the cell, for example by the dopamine transporter, to gain
access. TAAR1 is localized to distinct cellular compartments and
signals through different Gα proteins. Thus, cytoplasmic TAAR1
signals via Gαs and adenylyl cyclase, whereas TAAR1 localized
to the endoplasmic reticulum signals via Gα13, stimulating
the GTPase, RhoA (59). The involvement of these different
mechanisms in different aspects of TAAR1 effects is currently
unknown, as is the circuitry underlying TAAR1 agonist-induced
aversion. The lateral habenula (LHb) encodes negative prediction
errors and punishment signals, and LHb activation results in
aversive behaviors (60–62). Further, acute MA induces expression
of the immediate early gene, fos (63), and lesions of the
LHb increase amphetamine-induced stimulation (64). Based
on data indicating that glutamate-mediated synaptic plasticity
differentiates the MADR lines (15), and data demonstrating
differences between the MADR lines in glutamate responses to
MA (65, 66), future studies are planned to examine TAAR1
regulation of glutamate synapses in ventral tegmental area
dopamine neurons and dorsal raphe serotonin neurons, arising
from LHb afferents (67).
Because mice that lack functional TAAR1 are deficient in
the opposing aversion mechanism, they have the capacity to
experience MA reward. Individual variability in the strength
of the rewarding effect may be responsible for residual
variability in MA intake in the MAHDR line. Another
source of individual variability is genetic modifiers of the
Taar1m1J effect in homozygous individuals. We are examining
this in the heterogeneous stock—collaborative cross mice
developed by our collaborator, Dr. Robert Hitzemann, at
the VAPORHCS, which are the product of an 8-way cross
of mouse strains representing 89% of the genetic variability
present in mice (68, 69). We recently reported the successful
selective breeding of mice for higher and lower amounts

Potential Shortcomings and Limitations of
the Current Work
MA consumption was measured slightly differently at JAX in the
DBA/2J and C57BL/6J KI and control mice, compared to the
way in which it was measured in our previous studies of the
MADR lines and MAHDR KI and controls at the VAPORHCS.
At JAX, mice were given access to MA for 24 h/day vs. the
18 h/day established procedure at the VAPORHCS. The JAX
method is procedurally simpler, since bottles do not need to be
manipulated during the course of the day, as they do for the 18
h/day procedure. Although this reduces our ability to directly
compare MA intake amounts across studies conducted at the
two locations, there is no issue with evaluating genotype effects
using either procedure, as can be seen here and in our data
for the MAHDR KI and control mice (21). In fact, a previous
study found that MA intake was lower when offered to MAHDR
mice for 24 h/day, compared to 18 h/day, but that the difference
in MA intake between MAHDR and MALDR mice remained
robust (58).
Our MA-induced conditioned place preference, conditioned
taste aversion and hypothermia studies examined the effects of
only a single MA dose in each case. The dose used was chosen
from previous dose-response studies to reliably produce the
effects examined here (16, 18, 20, 27). Furthermore, we have
found mice with the Taar1m1J/m1J genotype to be insensitive to
the aversive and hypothermic effects of a wide range of MA doses
(20, 27); thus, we do not believe that testing additional doses
would change the general outcome of the associations described
here. Likewise, mice possessing the Taar1+ allele have exhibited
little to no sensitivity to rewarding or reinforcing effects of MA
(16, 42).
Our KI mice are produced by separate breeding pairs from
those that produce our control mice; thus, the mice are not
littermates. However, that is also the case for all mice that
possess each of these genotypes, with the exception of noninbred crosses. For example, the Taar1m1J mutation is found
in homozygous form in DBA/2J mice and in some strains of
the C57BL/6J × DBA/2J recombinant inbred (BXD RI) series
(21, 22, 24, 25). F2 crosses of these mice result in the 3
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of MA intake from a population of individuals that are
all homozygous for the Taar1m1J allele (70). These lines
will allow us to perform transcriptome analyses to identify
genetic differences that result in resistance to the enhancing
effect of the homozygous Taar1m1J genotype on MA intake,
information that could lead to the identification of a new class
of therapeutics.
We previously found that although Oprm1 is not a
quantitative trait gene for MA intake (71), it serves as a hub
when added to a network of differentially expressed genes
derived from nucleus accumbens, prefrontal cortex and ventral
midbrain samples from the MALDR and MAHDR lines (19).
We confirmed herein that Taar1 does not impact sensitivity to
morphine-induced hypothermia; rather, Oprm1 likely underlies
differential sensitivity to this morphine effect in the MADR lines.
This may also be the case for the differential morphine intake
of the MADR lines (28), though we have not yet examined
this trait in the KI mice. Buprenorphine reduced MA intake
in MAHDR mice without impacting total fluid consumption.
Lower doses were effective, but higher doses known to have
µ-opioid receptor antagonist effects were ineffective, as was
the µ-opioid receptor antagonist, naltrexone (28). Morphine,
on the other hand, reduced MA intake, but also total fluid
intake (71). This suggests that a partial agonist could serve
as a treatment to reduce MA intake. To determine whether
Oprm1 plays a role in the effectiveness of buprenorphine, we
intend to test BXD RI strain mice that have the high MA
intake Taar1m1J/m1J genotype, but are homozygous for either
the DBA/2J or C57BL/6J Oprm1 allele. If Oprm1 allele is
irrelevant, than effects on MA intake should be comparable
across strains.
Finally, it should be noted that Taar1 agonists and partial
agonists are being explored as therapeutics for MA addiction
and other neuropsychiatric conditions (72), and have shown
promise in animal models (73–75). Of course, the strategy of
increasing TAAR1-mediated activity with direct agonists requires
a functional receptor, and thus, is not an approach we have
been able to take in our genetic mouse models of absent TAAR1
function. However, we have collected data in mice possessing
the Taar1+ allele, and confirmed that TAAR1-specific agonists
have strong aversive effects (Shabani and Phillips, unpublished
data). It is possible that TAAR1 agonists reduce MA intake via
a substitution mechanism (75), but also possible that agonists
activate aversion circuitry that reduces the potency of MA
reward. We are not aware of reports directly characterizing the
subjective effects of TAAR1 agonists in humans.
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